The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account